Genetic mouse models have yielded conflicting conclusions about the role of PI3Ka in heart physiology: specifically, the question of whether PI3Ka has a direct role in regulating myocardial contractility. This has led to concerns that PI3K inhibitors currently in clinical trials for cancer may potentiate cardiotoxicity. Here we seek to clarify the role of PI3Ka in normal heart physiology and investigate changes in related signalling pathways.
Introduction
Phosphoinositide 3-kinase (PI3K) is a lipid kinase that functions as a central mediator of growth factor signalling through membrane receptor tyrosine kinases (RTKs). 1, 2 In the heart, the PI3K catalytic subunit p110a (PI3Ka) is the dominant isoform involved in growth factor signalling through RTKs, and has effects on organ and myocyte size, 3 as well as protective roles in models of heart disease, and is a mediator of the beneficial effects of exercise on the heart. 4 -6 The systemic effects of PI3K inhibition, including effects on the heart and vasculature, are of particular interest due to the numerous PI3K inhibitors in clinical trials for use as cancer therapies; PI3Ka, b, and d over activation have been implicated in cancer development and PI3K inhibitors may soon enter the clinic for use in cancer treatment.
PI3Ka deletion results in embryonic lethality in the mouse, 10 but the PI3Ka isoform has been studied extensively in the heart through a kinase null dominant negative model (PI3KaDN) expressed under the regulation of the cardiomyocyte specific a-myosin heavy chain (aMHC) promoter, which is activated shortly after birth. PI3KaDN hearts have reduced cardiomyocyte and heart size, 11 have an impaired response to pressure overload, and do not develop physiological hypertrophy upon swim training. 4, 5 However, without a pathological stimulus, PI3KaDN mice have normal heart function, 3, 6, 10, 11 are resistant to ischaemia/reperfusion injury, 12, 13 and show resistance to cardiac decline with age. 14 The catalytic isoform p110b (PI3Kb) has been implicated in neutrophil activation, 15 and promotes tumour growth in some tissues in a PTEN haploinsufficient mouse model. 16 PI3Kb is also expressed in the heart, although a specific signalling role for PI3Kb in cardiomyocytes has not been defined. In addition to the PI3KaDN model, PI3Ka and PI3Kb can also be studied in cardiomyocyte specific knockout mice through insertion of LoxP sites that flank the gene of interest. These mice can then be crossed to commercially available mice expressing Cre recombinase (Cre) under the aMHC promoter. To conditionally target these genes in only the adult heart, a Cre chimera is utilized in which Cre is fused to a mutated oestrogen receptor (MER) (MCM; MER-Cre-MER) which keeps Cre in the cytosol. Administration of the drug tamoxifen causes nuclear localization and activation of Cre. A constitutively active Cre can also be employed which does not require tamoxifen for activation, but does not allow for the same level of temporal control of the gene deletion. In sharp contrast to PI3KaDN hearts, which have normal function at baseline conditions, 3, 6, 11 the PI3Ka flx/flx MCM mice have been reported to display reduced contractility, with L-type Ca 2+ channels (LTCC) membrane depletion, suggesting a specific role for PI3Ka in maintaining normal contractility. 17 Interpretation of cardiac phenotypes from mice using the MCM model is complicated by the cardiotoxic effects from the combination of the Cre recombinase enzyme and tamoxifen. 18, 19 This study aims to clarify the cardiac phenotype of PI3Ka deletion or inhibition in the adult mouse; specifically, to determine if PI3Ka is required for normal myocardial contractility in the adult heart. Furthermore, we investigate alterations in important hypertrophic and metabolic signalling pathways that may partially compensate for PI3Ka deletion/inhibition.
Methods

Experimental animals and tamoxifen treatment
Mice with transgenic Cre recombinase either conditionally active (MCM) or constitutively active (Cre) under the control of the aMHC promoter (Jackson Lab) were crossed with mice carrying loxP sites targeting either the PI3Ka or PI3Kb genes (PIK3CA, PIK3CB respectively) as previously described. 20, 21 All mice used for this study were male in a C57Bl/6 background. Mice were housed on a 12 h dark/light cycle with free access to chow diet (#5001 Lab Diet) and water. All experiments were performed in accordance to institutional guidelines, Canadian Council on Animal Care and the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (revised 2011). Male mice 10 -11 weeks old were given tamoxifen (Sigma), dissolved in corn oil (concentration calculated for 4 mL/kg), by oral gavage daily for 4 days. The high dose (HD) of tamoxifen was 60 mg/kg/day and the low dose (LD) was 40 mg/kg/day.
Primary adult cardiomyocyte isolation and culture
For isolation of mouse cardiomyocytes, the mouse was anaesthetized with inhaled isoflurane (2%). The heart was removed and promptly perfused with a collagenase solution and myocytes isolated and cultured as previously described. 22 We modified the protocol by adding (S)-blebbistatin (25 mM;
Toronto Research Chemicals) used in 'stopping buffer' to inhibit cardiomyocyte contraction after isolation; also, ATP and BDM supplements were not used in media or buffers. 22 Human cardiomyocytes were isolated from a non-failing human donor heart which was obtained by the Human Organ Procurement and Exchange (HOPE) program. The above perfusion based protocol was modified as follows: LV tissue was pulled apart with fine forceps and stirred in digestion buffer with blebbistatin (25 mM) at 368C. After 20 min, digestion buffer was periodically removed and suspended cells were pelleted to determine the progress of the tissue digestion. Pelleted cells with rod shape morphometry were pooled as digestion continued ( 1 h), and fresh digestion buffer was added. Calcium reintroduction, plating, and culture were performed as for murine cardiomyocytes. After plating cells in media containing 10% serum, cardiomyocytes were cultured in serum free media with ITS supplement (Sigma) containing 10 mg/L insulin. For addition to culture media, BYL-719 (100 nM final concentration) dissolved in dimethyl sulfoxide (DMSO) was serially diluted to give final concentration of 0.005% DMSO in treated or vehicle control.
Measurement of cardiomyocyte contractility
Cardiomyocytes were isolated as described earlier, but blebbistatin was omitted to preserve contractile function. Following isolation, cardiomyocytes were kept in perfusion buffer solution (pH 7.4). An aliquot of isolated cardiomyocytes were transferred in a glass-bottomed recording chamber on top of inverted microscope (Olympus IX71) and allowed to settle for 5 -6 min. Cells were superfused at a rate of 1.5 -2 mL/min with modified Tyrode's solution (containing in mM): 135 NaCl, 5.4 KCl, 1.2 CaCl 2 , 1 MgCl 2 , 1 NaH 2 PO 4 , 10 Taurine, 10 HEPES, 10 glucose; pH 7.4 with NaOH). The superfusion solutions were heated to in-bath temperature of 35 -36 8C using in-line heater (SH-27B, Harvard Apparatus) controlled by automatic temperature controller (TC-324B, Harvard Apparatus). Quiescent rod-shaped cardiomyocytes with clear striations were selected for study. Platinum-wire electrodes were placed near the cell just outside of the microscope view at ×400 magnification. Cardiomyocytes were paced at 1 or 3 Hz with voltage of 3 -4 V (ca. 50% above threshold) an d pulse duration of 2.5 ms using S48 stimulator (Grass Technology). Sarcomere length was estimated in real time from images captured at a rate 200 frame/s via ×40 objective (UAPO 40X3/340, Olympus) using high-speed camera (IMPERX IPX-VGA-210, Aurora Scientific) as we have previously described. 23 At about 2 min of stimulation time, 5 -10 consecutive contractions were selected and averaged to reduce noise and make calculations of derivatives more precise. Averaged contraction was used to calculate fractional shortening (FS) and +dL/dt. Calculations were performed in Origin 8.5 (OriginLab) using custom-made script of built-in LabTalk language.
PI3Ka inhibitor (BYL-719) treatment
Male mice 16 -18 weeks old were given 30 mg/kg/day BYL-719 dissolved in corn oil (concentration calculated for 8 mL/kg) by oral gavage daily for 2 weeks, 5 days/week, or acutely once per day for 4 days. The dose of 30 mg/kg/day was previously shown to reduce the size of PI3Ka driven tumours in mice. 24 
Blood glucose measurements
Blood glucose was measured in fasted mice from a tail vein prick using the Ascensia Contour Blood Glucose Monitoring System (Bayer).
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Echocardiography and pressure-volume loop analysis
Non-invasive functional assessment was performed by transthoracic echocardiography using a Vevo 770 high resolution imaging system with 30 MHz transducer (RMV-707B; VisualSonics) under isoflurane anaesthetic (1.5 -2%) as previously described. 25, 26 Haemodynamic assessment was performed with a pressure transducer catheter (1.2 F admittance catheter; Scisense Inc.) under isoflurane anaesthetic (1.5 -2%) with the closed chest model previously described. 27 The catheter was inserted into the right carotid and advanced into the left ventricle as indicated by the pressure reading using the ADVantage Pressure-Volume System (Scisence Inc.) with iworx LabScribe2 software for data recording and analysis (iWork Systems Inc.).
Western blots, RT-PCR, and histology
Hearts were removed with mice under ketamine (100 mg/kg)/xylazine (10 mg/kg) anaesthesia and snap frozen for western blots and RT -PCR, or arrested with 1 M KCl saline solution and preserved in 10% formalin Figure 1 Tamoxifen treatment induces transient systolic dysfunction in MCM transgenic mice with PI3Ka dependent recovery. Representative echocardiography M-mode images of left ventricle and left atrium (A-C) (UT, untreated; HD, high-dose tamoxifen) showed MCM transgenic mice had normal heart function before tamoxifen treatment (n ¼ 10) (A). HD tamoxifen caused contractile dysfunction and left atrium dilation at 10 days from start of tamoxifen treatment in MCM controls (n ¼ 7) and PI3Ka MCM (n ¼ 7) (B). MCM transgenic control, but not PI3Ka MCM mice recovered heart function and left atrium dimensions by 28 days after start of tamoxifen treatment (C). Summary ejection fraction (EF) and left atrium (LA) measurements are shown for all groups (D). All mice are MCM transgenic; *P , 0.05 (tamoxifen treated groups at 10 days or 28 days compared with UT by one-way ANOVA; analysis performed according to predefined comparison to normal functioning untreated group).
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for histology. For TaqMan RT -PCR, RNA was isolated in TRIzol (Invitrogen) using a TissueLyser II (Qiagen) to homogenize samples and converted to cDNA and quantified in comparison to 18S rRNA used as a load control as previously described. 27 For western blots, left-ventricular tissue was homogenized using a TissueLyser II in CelLytic M Cell Lysis Reagent (Sigma) with cOmplete and PhosSTOP inhibitors (Roche). Upon transfer to Immobilon PVDF membranes (Millipore), all antibodies used were from Cell Signaling except Phospholamban (Badrilla) and SERCA2a (Thermo). PVDF membranes were stained for total protein as a loading control using MemCode (Thermo). Myocardial histological sections were stained with Picrosirius red as described previously. 28 TUNEL staining was performed as previously described. 25 
Statistical analysis
Two groups were compared using a non-paired Student's t-test. Three or more groups with a single variable were compared using a one-way ANOVA with Neuman-Keuls post-hoc test. Two-way ANOVA was used for two groups with two subgroups (i.e. two genotypes with two treatments). Analysis was performed using SPSS 19 software. Values are shown as mean +SEM, with significance indicated by *P ≤ 0.05.
Results
Oral administration of tamoxifen in food (80 mg/kg/day for 7 days) was previously reported to cause effective gene deletion in MCM/ [gene] flx/flx . 19 We adopted an oral gavage regimen in order to closely control tamoxifen dosing. We observed considerable morbidity and mortality at higher tamoxifen doses in MCM transgenic mice (80 mg/kg/day for 5 days, data not shown) and we found that 4 days of 60 mg/kg/day tamoxifen (high dose; HD) was tolerated with no mortality. Heart function, assessed by echocardiography, was significantly reduced in the PI3Ka MCM transgenic models at 10 days from the start of treatment ( Figure 1A and B) ( Table 1) . We assessed heart function again at 28 days, and observed functional recovery in MCM transgenic controls (no flx targeted genes). However, PI3Ka MCM mice had continued severe systolic dysfunction ( Figure 1C and D), suggesting a critical role for PI3Ka in recovering normal heart function after tamoxifen/Cre toxicity. We reduced the tamoxifen dose to 4 days of 40 mg/kg/day (low dose; LD), and observed normal heart function at 10 days from the start of tamoxifen treatment (Figure 2A and B) ( Table 2) , and maintained effective loss of the target protein ( Figure 2C) . Similarly, cardiomyocytes isolated from PI3Ka MCM treated with LD tamoxifen had normal function compared with untreated controls ( Figure 2D ). Combined, these results demonstrate a role for PI3Ka in recovery from Cre/tamoxifen toxicity, but not a direct role in heart function. PI3Kb MCM mice treated with HD tamoxifen followed the same phenotype as MCM controls, with reduced heart function at 10 days from the start of tamoxifen and recovery to normal function at 28 days ( Figure 2E and F ) . PI3Kb protein was significantly reduced in this model ( Figure 2F) .
In addition to reduced function, tamoxifen/Cre toxicity was previously characterized by transient increases in expression of genes associated with heart disease at Day 10, but resolved by Day 28 from the start of tamoxifen treatment. 19 We observed PI3Ka MCM HD mice had elevated expression of markers of heart disease: expression of ANF, BNP, and a-skeletal actin, but not b-myosin heavy chain at 28 days ( Figure 3A) , suggesting a continuation of the acute tamoxifen/Cre toxicity phenotype. Tamoxifen/Cre toxicity can also cause increased myocardial fibrosis 29 ; we observed elevated transcription of collagen III and increased myocardial fibrosis in PI3Ka MCM HD hearts but not LD hearts ( Figure 3B and C) compared with MCM HD controls. We did not detect a significant level of apoptotic cells in any of the groups at the 28 day time point (Supplementary material online, Figure S1 ). The PI3Ka MCM LD did not deviate from controls in disease markers or collagen expression ( Figure 3A and B) using ANOVA analysis. However, comparison of only control and PI3Ka MCM LD (data not shown) did show significant increase (P ¼ 0.034) in ANF expression which was also previously observed in PI3KaDN hearts, 11 and may have a beneficial effect due to anti-hypertrophic and anti-fibrotic properties. 30 Western blot analysis was performed to investigate changes in signalling pathways related to PI3Ka signalling. Akt activation (P-Akt Thr) was PI3Ka in myocardial insulin signalling and contractility consistently low in both HD and LD tamoxifen-treated PI3Ka MCM models, but Akt activation levels were highly variable in MCM control hearts, so Akt activation was not significantly different between groups ( Figure 3D ). We suspect that this is due to variations in plasma insulin levels because we did not control feeding prior to sacrifice. To better clarify the level of PI3Ka activity, we adapted a model of fasting and acute insulin administration in subsequent models. In this way, Akt activation can serve as a marker of PI3Ka activity. We also wanted to confirm in mouse and human adult cardiomyocytes that PI3Ka is a key transducer of insulin signalling. 31 We observed increased MAPK ERK1/2 activation in PI3Ka MCM hearts with LD, but not HD tamoxifen ( Figure 3D ). We also previously reported increased MAPK ERK1/2 phosphorylation of PI3KaDN hearts in setting of ischaemia/reperfusion in a working heart model 12 ;
others have also shown increased P-ERK activation in PI3KaDN hearts 5 and pharmacological inhibition of PI3K in SkBr3 cells with PI3K inhibitors BEZ235, LY294002, and wortmannin all caused increased ERK1/2 phosphorylation. 32 Activated ERK1/2 can lead to hypertrophy, and has important cardio-protective roles in the setting of cardiac injury and failure. 33 Activation of AMPK by phosphorylation was observed in LD PI3Ka MCM hearts, and IRS-1, which can be controlled by negative feedback downstream of PI3K, 34 was increased in LD and HD PI3Ka MCM hearts. The SERCA2a pump and its regulator phospholamban (PLN) were not changed from control hearts ( Figure 3E) . In contrast to the MCM model, the constitutively active Cre transgenic model does not allow for a temporally controlled knockout; under the aMHC promoter, Cre is likely active perinatally, 35 with the potential for developmental effects from absent PI3Ka signalling and possible toxicity from constitutively active Cre recombinase. 36 However, no tamoxifen is needed to activate Cre, so there is no chance of tamoxifen/Cre toxicity.
With this model, we observed normal heart function ( Figure 4A and B) ( Table 3 ) and normal contractility of isolated cardiomyocytes ( Figure 4C ). To investigate in-vivo signalling in PI3Ka Cre hearts, mice were fasted overnight and then received an acute injection of insulin 15 min before sacrifice ( Figure 4E ). PI3Ka Cre mice had impaired insulindependent activation of Akt, and constitutively higher activation of ERK1/2 independent of insulin stimulation. IRS-1 levels increased after insulin stimulation consistent with previous findings, 37,38 but had higher overall levels in PI3Ka Cre mice. Activation of AMPK was also increased in PI3Ka Cre hearts. In contrast, PI3Kb Cre knockout mice did not have reduced insulin-mediated activation of Akt in the heart (Supplementary material online, Figure S2 ). Alpha skeletal actin expression was significantly increased in PI3Ka Cre ( Figure 4F ), but not in LD-treated PI3Ka MCM ( Figure 3A) , suggesting that this may be a byproduct of the unique characteristics of the Cre model (expressed early in development, constitutively active Cre).
The PI3Ka specific inhibitor BYL-719 39 blocked insulin-mediated activation of Akt in vivo in the mouse heart, and in vitro in mouse and human adult cardiomyocytes ( Figure 5A and B). PI3Ka inhibition also caused increased activation of ERK1/2 and AMPK signalling, but did not affect protein levels of p110a or IRS-1 ( Figure 5B ). Treatment of wt mice with BYL-719 did not result in alterations in cardiac function after 2 weeks of treatment ( Figure 5C and F ). Echocardiography and P/V loop measurements were performed 3 days after the end of drug treatment to avoid any acute drug effects. Consistent with the established role of PI3Ka in regulating insulin signalling and glucose metabolism, 40 fasting glucose levels were elevated after the first week of treatment with BYL-719 ( Figure 5D ). Treated mice also had significant weight loss after 2 weeks of treatment ( Figure 5E ). The expression of disease markers did not change between vehicle treated and 4-day or 2-week BYL-719-treated mice ( Figure 5G ).
Discussion
The PI3K signalling pathway is a critical regulator of myocardial structure and function in development and pathophysiology. 1 -3,41 The MCM and
Cre models for PI3Ka deletion are an important expansion on research performed with the PI3KaDN model because they offer a true deletion of the gene for either PI3Ka or PI3Kb, and the MCM model allows for gene deletion in the adult, avoiding complications due to developmental roles for these kinases. Oral administration of tamoxifen sufficient to cause gene deletion was previously shown to cause a transient reduction in cardiac function at 10 days after starting the drug, with full recovery of function at 28 days. 19 This led us to hypothesize that loss of PI3Ka may increase susceptibility to tamoxifen/Cre toxicity, but may not be necessary for preserved heart function. Increased awareness for Cre/tamoxifen toxicity has prompted investigators to now favour a minimal dose of tamoxifen to cause gene deletion. 42 Although we observed functional recovery in our HD tamoxifen control group (Figure 1) , there may be residual damage present that could not be captured by the methods we used. After observing that PI3Ka deletion impaired recovery from tamoxifen/Cre toxicity, our primary aim in this study was not to determine the precise mechanism of the resulting cardiomyopathy, but rather to avoid this compounding variable in our study of PI3Ka signalling in relation to heart function, which is why we tested a reduced tamoxifen dose as well as other complementary models of PI3Ka deletion/inhibition that do not require tamoxifen. Numerous genetic models have shown a complex role for PI3Ka in diverse cardiovascular pathophysiological processes, with both beneficial and detrimental effects from loss of PI3Ka. We observed normal PI3Ka in myocardial insulin signalling and contractility Figure 3 Molecular and histological changes in tamoxifen treated PI3Ka MCM at 28 days after start of tamoxifen. Expression of disease markers Nppb (BNP), Nppa (ANF), and Acta1(a-skeletal actin) but not Myh7 (b-MHC) were increased in HD PI3Ka MCM but not LD PI3Ka MCM or control MCM tamoxifen treated mice at 28 days after start of tamoxifen compared with untreated (UT) controls (n ¼ 5) (A). Expression of Col1a1 and Col3a1 (collagen I and III); Col3a1 was increased in HD PI3Ka MCM but not LD PI3Ka MCM or control MCM tamoxifen-treated mice at 28 days after start of tamoxifen compared with UT (n ¼ 5) (B). Representative images from histological sections stained for collagen with Picrosirius Red (PSR) and quantification of collagen volume fraction (CVF) (n ¼ 3 hearts; averaged from 3 to 4 images/heart) (C). Western blots for changes in activation or protein levels at 28 days after start of tamoxifen for Akt (Thr 308), IRS-1, ERK1/2, and AMPK (Thr 172) (D); and SERCA2a and PLN (phospholamban) (Ser 16) in HD MCM, HD PI3Ka, and LD PI3Ka (n ¼ 8) (E). All mice are MCM transgenic; *P , 0.05.
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Figure 4
Loss of PI3Ka in constitutively active Cre model does not significantly affect heart or myocyte function but blocks insulin signalling. Representative echocardiography M-mode images of the left ventricle in PI3Ka Cre (n ¼ 9) and no Cre (n ¼ 6) mice and summary ejection fraction (EF) show normal function (A). Representative pressure/volume loops for PI3Ka Cre (n ¼ 9) and no Cre (n ¼ 10) mice and summary haemodynamic parameters from pressure volume loops: ejection fraction, peak maximal, and minimal change in pressure per unit time (dP/dt), maximal change in pressure per unit time divided by end diastolic volume (EDV) and end systolic pressure volume relationship (ESPVR) (B). Fractional shortening and maximal change in length per unit time (+dP/dt) of isolated adult cardiomyocytes from PI3Ka Cre and control mice paced at 1 Hz (n ¼ 11,18) and 3 Hz (n ¼ 10, 16) from 2 and 4 isolations, respectively (NS,not statistically significant) (C). Representative western blot for PI3K p110a showing loss of p110a protein in LV of constitutively active Cre (n ¼ 6) (D). Western blots from LV tissue of PI3Ka Cre and No Cre mice fasted overnight (16 h), with and without acute insulin stimulation by IP injection (1 mg/kg) and hearts collected after 15 min; changes in activation or protein levels of Akt, IRS-1, ERK, and AMPK (significant effect of insulin ($) and/or genotype (#) (n ¼ 6) (E). Expression of disease markers: Nppb (BNP), Nppa (ANF) Myh7 (b-MHC) were not changed but Acta1(a-skeletal actin) was increased (n ¼ 11 -12) (F). *P , 0.05. PI3Ka in myocardial insulin signalling and contractility heart function in PI3Ka MCM LD and PI3Ka Cre models, despite loss of PI3Ka, and normal heart function after 2 weeks of PI3Ka inhibition with BYL-719. Therefore, we conclude that loss of PI3Ka is not inherently pathological to the heart in otherwise healthy mice, and specifically does not directly regulate heart contractility in these models. Our results are consistent with the normal functioning cardiac phenotype observed in PI3KaDN hearts. 3, 6, 11 We allowed drug washout before functional phenotyping of the BYL-719 treated group to specifically examine persisting effects of PI3Ka inhibition on myocardial contractility. We avoided functional phenotyping of acute treatment with BYL-719 to avoid possible off-target effects seen with other PI3K inhibitors, 43 and complicating factors, such as alterations in metabolic substrate utilization, which may alter myocardial efficiency. 44 This study does not exclude all possibility of on or off-target effects on heart function of PI3K inhibitors and we urge further investigation of cardiac effects of PI3K inhibitors now in clinical trials. ERK1/2 activation has been associated with hypertrophy and cellsurvival effects, 45 and enhanced ERK1/2 signalling in PI3Ka MCM and PI3Ka Cre hearts may partially compensate for loss of PI3Ka due to overlapping roles in cell survival signalling. One possible mechanism of ERK1/2 activation is through reduced negative feedback downstream of PI3K that affects upstream elements common to both PI3K and ERK1/2 signalling pathways. IRS-1 is negatively regulated by the PI3K pathway 34 ; PI3Ka haploinsufficient mice display increased IRS-1 protein levels and maintained insulin sensitivity with age. 46 Increased IRS-1 may partially explain increased ERK1/2 activation, 47 but IRS-1 levels were increased in both HD and LD PI3Ka MCM hearts ( Figure 3D ), despite ERK1/2 activation only being increased in the LD treated mice, so there are likely to be other regulatory factors also influencing ERK1/2 activation. Interestingly, ERK1/2 signalling has an important role in cell survival and proliferation in the setting of PI3K class IA isoform inhibition in haematopoietic progenitor cells and fibroblasts. 48 Consequently, increased ERK1/2 signalling in PI3Ka MCM LD but not HD tamoxifen-treated mice may contribute to the disparity in the pathology between these two groups. AMPK is an energy conserving mechanism activated in the setting of low insulin signalling, 49 and is consistent with reduced Akt activation and impaired insulin signalling in the PI3Ka MCM hearts. 17 AMPK activation may have an adaptive role in the setting of mild metabolic stress, due to AMPK-mediated inhibition of energy demanding processes such as protein synthesis. 50 Similarly, AMPK may be beneficial for energy homeostasis in PI3Ka MCM hearts ( Figure 3D ), but may inhibit cellular stress responses needed to reduce tamoxifen cytotoxicity in HD tamoxifen-treated hearts. Our findings showing enhanced AMPK and ERK1/2 signalling in these PI3Ka deletion/inhibition models are indicative of the potential for cellular adaptation, and we expect that many more cellular regulatory pathways are also modified in these models. The resulting phenotypes are likely a complex combination of the loss of PI3Ka specific signalling, such as insulin and IGF-1, 51 and adaptations through altered regulation of other signalling pathways. PI3Ka MCM mice with LD tamoxifen may be an ideal genetic model for further studying the role of PI3Ka in the heart, along with the new generation of clinically targeted PI3K inhibitors such as BYL-719. We have observed that PI3Ka is critical for insulin-mediated activation of Akt in the heart, but further studies are needed to investigate the ramifications for this loss of Akt activation on heart metabolic substrate utilization. We observed marked weight loss in mice treated with the PI3Ka inhibitor BYL-719. Future studies looking at the effects of PI3Ka inhibitors on food consumption, whole body metabolism, and body composition would be useful. Weight loss due to skeletal muscle sarcopenia can have serious negative consequences for cancer patients, 52 and it is possible that PI3Ka inhibitors may promote this process. Interestingly, human cases with the converse, elevated PI3K activity due to PTEN haploinsufficiency, have increased insulin sensitivity and are more likely to be obese. 53 Our data and previous studies have clearly documented that PI3Ka is the dominant isoform which controls insulin-mediated signalling in the heart with a secondary regulatory role for PI3Kb. 17, 31 We would also speculate that considering the dramatic difference in PI3Ka-mediated activation of Akt between fasted and insulin-stimulated control mice ( Figures 4E and 5B), it does not seem practical to the organism for this system to also regulate heart function, because the act of eating and insulin release may not closely correlate with times when extra cardiac function is required. Cre, Cre recombinase transgenic; PI3Ka flx/flx denotes flx gene; HD, high-dose tamoxifen(60 mg/kg*4 days); LD, low-dose tamoxifen (40 mg/kg*4 days); HR, heart rate; E-wave, peak early transmitral inflow velocity; A-wave, transmitral inflow velocity due to atrial contraction; E ′ , early diastolic tissue Doppler velocity; A ′ , late diastolic tissue Doppler velocity due to atrial contraction; LVEDD, left-ventricular (LV) end-diastolic diameter, LVESD, LV end systolic diameter; LVFS, LV fractional shortening; LVEF, LV ejection fraction; VCEc, velocity of circumferential shortening corrected for heart rate; LVPWT, LV posterior wall thickness. Values are mean + SEM. *P , 0.05 compared with corresponding control. Figure 5 PI3Ka inhibition with BYL-719 causes weight loss and blocks insulin signalling, but does not affect heart function. Western blot representative image and quantification for Akt activation are shown for wild-type adult mouse cardiomyocytes (average and standard error of change from placebo control to BYL-719 treated myocytes from 3 to 4 replicates obtained independently from n ¼ 4 mouse hearts) and representative western blot of human non-failing cardiomyocytes (from n ¼ 2 donor hearts) cultured with insulin (10 mg/L) supplemented media (12 h) with and without BYL-719 (A). Insulin signalling was tested after a 4-day treatment (30 mg/kg/day BYL-719) with mice fasted 16 h overnight before their final dose of BYL-719. Three hours later, mice were injected with insulin (1 mg/kg) and hearts collected after 15 min (n ¼ 4); western blots investigated effect of insulin ($) and/or BYL-719 (#) On protein levels or activation of p110a, IRS-1, Akt (Thr 308), ERK1/2, and AMPK (Thr 172) (n ¼ 4) (B). Representative echocardiography M-mode images of left ventricle (LV) of vehicle (oil) or BYL-719 and summary of ejection fraction (EF)% from echocardiography of 2 weeks of vehicle (oil) and BYL-719 treated (n ¼ 8-9) (C). Fasted blood glucose measured the day following first 5 days of treatment with BYL-719 (30 mg/kg/ day) after fasting overnight for 16 h (n ¼ 6) (D). Change in body weight after 2 week administration of BYL-719 (30 mg/kg/day*5 days/week) for vehicle or BYL-719 treated mice (n ¼ 8-9) (E). Representative pressure/volume loops for vehicle or BYL-719 treated mice and summary haemodynamic parameters from pressure volume loops: ejection fraction, peak maximal and minimal change in pressure per unit time (dP/dt), maximal change in pressure per unit time divided by end diastolic volume (EDV) and end systolic pressure volume relationship (ESPVR) for vehicle (oil) (n ¼ 5) and BYL-719 (n ¼ 7) treated mice (F). Expression of disease markers in oil treated compared with 4-day and 2 weeks of BYL-719 treatment (n ¼ 6 -7 each) (G). *P , 0.05.
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The genetic and pharmacological models of PI3K loss/inhibition are timely models for predicting the effect on the heart of PI3K inhibition considering the current trials for PI3K inhibitors in adults with cancer. 4, 5, 9 Our observation in this study, that PI3Ka loss reduced the ability for recovery from tamoxifen/Cre cardiotoxicity suggests that PI3Ka has important cardioprotective properties, and future studies should investigate the impact of PI3Ka inhibition in patients with common comorbidities and risk factors such as advanced age, hypertension, coronary artery disease, metabolic syndrome, and combinations with other cancer therapies. On the flipside of PI3K inhibition for cancer patients, activation of PI3Ka signalling, such as through exercise
